A stabilised form of HMT (hydromethylthionine mesylate, HMTM) was developed to permit the direct administration of HMT for the treatment of Alzheimer’s disease (AD) [3,4,6,7,8] because HMT is a potent tau aggregation inhibitor [9]. The gene discussed is MAPT; the disease is Alzheimer disease.